Clearmind Medicine Inc. CMND, a clinical-stage biotech firm based in Vancouver, has been granted a new patent by the United States Patent and Trademark Office. As the company stated in a press release, this approval marks a significant milestone in Clearmind's efforts to develop psychedelic-derived therapeutics, particularly in its MEAI-based program aimed at regulating binge behavior.
The Innovative Compound Behind Clearmind's Success
The newly approved patent covers methods for regulating alcohol consumption and controlling binge behavior through the administration of amine aminoindane, including the innovative compound 5-methoxy-2-aminoindan (MEAI). MEAI is a novel psychoactive molecule designed to reduce the urge to consume alcohol while providing a mild, alcohol-like euphoric experience. This compound is at the core of Clearmind's efforts to address Alcohol Use Disorder (AUD), a condition that ranges from mild to severe and affects millions globally.
Clearmind’s Growing Patent Portfolio And Global Reach
Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized the importance of this patent in the company's broader strategy. "We are proud to continue leading the way in IP protection within this space. Expanding and maintaining our patent portfolio, particularly in the U.S., remains a key objective for us. We believe that we hold one of the largest portfolios in the market, covering our core areas: MEAI, binge behavior, addictions, mental disorders, as well as new psychedelic compounds and combinations identified and researched by our team."
The patent adds to Clearmind's growing intellectual property portfolio, which now includes 29 granted patents across 19 patent families, with protections in major markets such as the U.S., Europe, China and India. This extensive portfolio underscores the company's commitment to pioneering treatments for under-treated health issues, particularly those related to alcohol consumption and mental health.
Cover image made with AI
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.